Report on therapyAdverse reactions to nitrofurantoin: Analysis of 921 reports
References (15)
- et al.
Metabolic activation of nitrofurantoin—possible implications for carcinogenesis
Biochem Pharmacol
(1979) - et al.
Drug evaluation after marketing
Ann Intern Med
(1979) - et al.
Adverse drug reactions during treatment of urinary tract infections
Eur J Clin Pharmacol
(1977) Adverse drug reactions
J Clin Pharmacol
(1973)- et al.
Drug-induced cytopenias in Sweden
Br Med J
(1973) - et al.
A three-year prescription study (in Swedish)
Sven Farmaceutisk Tidskri
(1977) - Holmberg L, Boman G: Pulmonary reactions to nitrpfurantoin in Sweden 1966-76. Submitted to Eur J Respir...
Cited by (194)
Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury
2023, Journal of HepatologyNitrofurantoin 100 mg versus 50 mg prophylaxis for urinary tract infections, a cohort study
2022, Clinical Microbiology and InfectionCitation Excerpt :Given our relatively short follow-up period, we may have missed consultations for chronic pneumonitis. If recognized early with discontinuation of nitrofurantoin, prognosis of both entities is on average good; however, serious irreversible lung damage could also occur and fatalities have been described [19,20]. It was already known that macrocrystalline nitrofurantoin prophylaxis is associated with a higher incidence of gastrointestinal adverse events when compared with other antimicrobials, with relative ratios of 2.24 (95% CI 1.77–2.83) and 2.17 (95% CI 1.34-3.50) in two meta-analyses [8,9,21].
Drug-Induced Liver Injury
2022, Comprehensive PharmacologyNitrofurantoin
2022, Comprehensive PharmacologyEpidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury
2020, Clinics in Liver DiseaseRespiratory
2020, An Introduction to Interdisciplinary Toxicology: From Molecules to Man
- 1
From the Departments of Medicine and Thoracic Medicine, Karolinska Hospital, Stockholm.
- 3
From the National Corporation of Pharmacies, Stockholm, Sweden.
- 2
From the Adverse Drug Reaction Committee, National Board of Health and Welfare, Uppsala; Pharmacia Norden Inc., Uppsala.